Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21354617 | 0.95 | MAP3K5 (0.30) | CCNT1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL18779252 | 0.89 | MAP3K5 (0.32) | CCNT1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL18779175 | 0.89 | KCNQ2 (0.35) | CCNT1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL18791920 | 0.86 | MAP3K5 (0.30) | CCNT1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL18779220 | 0.85 | ECE1 (0.33) | CCNT1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL30315571 | 0.85 | ECE1 (0.33) | CCNT1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL18779217 | 0.85 | MAP3K5 (0.33) | CCNT1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL18791658 | 0.84 | ACSS2 (0.35) | — | |
| SCHEMBL20111237 | 0.84 | ACSS2 (0.35) | — | |
| SCHEMBL18791922 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | ALDH1A1 3093/4885CCNT1 3713/4885CDK4 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.